Patients with SH3BP5+ DLBCL and LMO3+ DLBCL who were treated with chemotherapy without rituximab showed worse OS than patients with SH3BP5− DLBCL and LMO3− DLBCL; however, OS for patients treated with rituximab‐containing chemotherapy was sufficiently improved regardless of the expression of these two proteins. Here, LMO3 is linked to diffuse large B-cell lymphoma.